These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12665646)

  • 1. Molecular pathobiology of thyroid neoplasms.
    Tallini G
    Endocr Pathol; 2002; 13(4):271-88. PubMed ID: 12665646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular events in follicular thyroid tumors.
    Kroll TG
    Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
    Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
    Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
    Maciel RM; Kimura ET; Cerutti JM
    Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathogenesis of thyroid nodules and cancer.
    Moretti F; Nanni S; Pontecorvi A
    Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):517-39. PubMed ID: 11289733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
    Lacroix L; Mian C; Barrier T; Talbot M; Caillou B; Schlumberger M; Bidart JM
    Eur J Endocrinol; 2004 Sep; 151(3):367-74. PubMed ID: 15362967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
    Komminoth P
    Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
    Elisei R; Romei C; Vorontsova T; Cosci B; Veremeychik V; Kuchinskaya E; Basolo F; Demidchik EP; Miccoli P; Pinchera A; Pacini F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3211-6. PubMed ID: 11443191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
    Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
    Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
    Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
    Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oncogenes and thyroid tumors].
    Lacroix L; Soria JC; Bidart JM; Schlumberger M
    Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a paired box gene 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARgamma) rearrangement mosaicism in a patient with an autonomous functioning follicular thyroid carcinoma bearing an activating mutation in the TSH receptor.
    Lado-Abeal J; Celestino R; Bravo SB; Garcia-Rendueles ME; de la Calzada J; Castro I; Castro P; Espadinha C; Palos F; Soares P; Alvarez CV; Sobrinho-Simões M; Cameselle-Teijeiro J
    Endocr Relat Cancer; 2010 Sep; 17(3):599-610. PubMed ID: 20427420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
    Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
    Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.
    Zhu Z; Gandhi M; Nikiforova MN; Fischer AH; Nikiforov YE
    Am J Clin Pathol; 2003 Jul; 120(1):71-7. PubMed ID: 12866375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
    Zhu XL; Zhou XY; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicular, papillary, and "hybrid" carcinomas of the thyroid.
    Castro P; Fonseca E; Magalhães J; Sobrinho-Simões M
    Endocr Pathol; 2002; 13(4):313-20. PubMed ID: 12665649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.